Agilent's Q3 Net Income Soars 19% on Strong Revenue Growth

TL;DR

**Agilent's Q3 numbers are solid, but watch those federal funding cuts – they could be a headwind.**

AI Summary

Agilent Technologies, Inc. reported a robust financial performance for the three months ended July 31, 2025, with total net revenue increasing by 10.1% to $1,738 million from $1,578 million in the prior year. Net income saw a significant jump of 19.1% to $336 million, up from $282 million in the same period last year. For the nine months ended July 31, 2025, total net revenue grew by 5.8% to $5,087 million from $4,809 million, although net income slightly decreased by 7.4% to $869 million from $938 million. The company's new segment structure, implemented in November 2024, now includes Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. Key changes include a 17.5% increase in cost of products to $577 million for the three months ended July 31, 2025, and a 10.8% increase in selling, general and administrative expenses to $417 million. The company also repurchased $340 million of common stock during the nine months ended July 31, 2025, compared to $815 million in the prior year, indicating a shift in capital allocation. Risks include global economic conditions, foreign currency fluctuations, and U.S. federal government funding reductions impacting customer demand.

Why It Matters

Agilent's strong Q3 performance, particularly the 19.1% net income increase, signals robust demand in the life sciences and diagnostics sectors, which is crucial for investors looking for growth in healthcare technology. The strategic reorganization into three market-focused segments aims to enhance customer engagement and operational efficiency, potentially strengthening its competitive position against rivals like Thermo Fisher Scientific and Danaher. For employees, this growth could mean increased job security and opportunities, while customers benefit from continued innovation in laboratory solutions. The broader market gains confidence from a healthy player in a critical industry, despite ongoing risks from U.S. federal funding cuts and global economic volatility.

Risk Assessment

Risk Level: medium — The risk level is medium due to the company's exposure to U.S. federal government funding reductions, which have 'adversely impacted' their business, as stated in the filing. While revenue and net income are up for the quarter, the nine-month net income decreased by $69 million, or 7.4%, from $938 million to $869 million, indicating some underlying pressures. Additionally, the fair value of senior notes is $3,143 million compared to a carrying value of $3,329 million, reflecting increased market interest rates.

Analyst Insight

Investors should consider Agilent's strong Q3 performance as a positive indicator, but remain vigilant regarding the impact of U.S. federal funding cuts on future revenue. Monitor the company's ability to mitigate these risks through its new segment structure and diversified market approach. A 'hold' position is advisable, with an eye on upcoming guidance regarding government contracts.

Financial Highlights

revenue

$1,738 million

operating Margin

20.7%

total Debt

$3,350 million

net Income

$336 million

eps

$1.18

gross Margin

57.7%

cash Position

$1,535 million

revenue Growth

+10.1%

Revenue Breakdown

Key Numbers

• $1,738 million — Total net revenue (Q3 2025) (Increased by 10.1% from $1,578 million in Q3 2024)
• $336 million — Net income (Q3 2025) (Increased by 19.1% from $282 million in Q3 2024)
• $5,087 million — Total net revenue (YTD 2025) (Increased by 5.8% from $4,809 million in YTD 2024)
• $869 million — Net income (YTD 2025) (Decreased by 7.4% from $938 million in YTD 2024)
• $340 million — Payments for repurchase of common stock (YTD 2025) (Decreased from $815 million in YTD 2024)
• $1.18 — Diluted net income per share (Q3 2025) (Increased from $0.97 in Q3 2024)
• $3.05 — Diluted net income per share (YTD 2025) (Decreased from $3.20 in YTD 2024)
• $1,535 million — Cash and cash equivalents (July 31, 2025) (Increased from $1,329 million at October 31, 2024)
• $3,350 million — Long-term debt (July 31, 2025) (Slightly increased from $3,345 million at October 31, 2024)
• 283,500,427 — Shares of common stock outstanding (August 21, 2025) (Reflects share repurchases)

Key Players & Entities

• AGILENT TECHNOLOGIES, INC. (company) — registrant
• U.S. Securities and Exchange Commission (regulator) — regulatory body
• FASB (regulator) — Financial Accounting Standards Board
• New York Stock Exchange (regulator) — exchange where common stock is registered
• Life Sciences and Diagnostics Markets (company) — new business segment
• Agilent CrossLab (company) — new business segment
• Applied Markets (company) — new business segment
• Delaware (company) — state of incorporation

FAQ

Risk Factors

• Global Economic Conditions [high — market]: Deterioration in global economic conditions could negatively impact customer demand for Agilent's products and services. This is a persistent risk that could affect revenue growth.
• Foreign Currency Fluctuations [medium — financial]: Agilent operates globally, making it susceptible to fluctuations in foreign currency exchange rates. Adverse movements can impact reported revenues and profitability.
• U.S. Federal Government Funding [medium — regulatory]: Reductions in U.S. federal government funding could decrease demand from government-funded research institutions and agencies, impacting sales in specific market segments.
• Supply Chain Disruptions [medium — operational]: While not explicitly detailed in the provided text, disruptions in the supply chain for components or raw materials could impact production and delivery of products, affecting revenue and margins.
• Competitive Landscape [medium — market]: The markets in which Agilent operates are competitive. Failure to innovate or maintain competitive pricing could lead to market share erosion.

Industry Context

Agilent Technologies operates in the life sciences, diagnostics, and applied chemical markets, which are characterized by innovation, regulatory oversight, and demand from research, clinical, and industrial sectors. Key trends include the increasing adoption of advanced diagnostics, personalized medicine, and the need for robust analytical instruments for quality control and research. The competitive landscape includes other major players in laboratory instrumentation, consumables, and services.

Regulatory Implications

The company faces regulatory scrutiny, particularly concerning U.S. federal government funding, which can directly impact demand from research institutions. Compliance with various international regulations for medical devices and laboratory equipment is also critical for market access and sustained operations.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]
4. [object Object]

Key Dates

• 2025-07-31: End of Third Quarter 2025 — Reported strong revenue and net income growth for the quarter, indicating positive short-term performance.
• 2025-07-31: End of Nine Months 2025 — Reported revenue growth but a decrease in net income year-over-year, suggesting margin pressures or increased expenses over the longer term.
• 2024-11-01: Implementation of New Segment Structure — Marks a change in how the company reports its business segments, potentially impacting comparability of future segment-level performance.
• 2025-10-31: End of Fiscal Year 2024 — Previous fiscal year-end, used as a comparison point for current balance sheet items like cash and debt.

Glossary

Cost of products

Direct costs associated with manufacturing the goods sold by the company. (An increase of 17.5% to $577 million in Q3 2025 suggests rising input costs or changes in product mix.)

Selling, general and administrative expenses (SG&A)

Costs incurred for marketing, sales, and general administrative functions of the business. (An increase of 10.8% to $417 million in Q3 2025 indicates higher operational spending, potentially for growth initiatives or increased operational scale.)

Diluted net income per share

Net income divided by the total number of diluted shares outstanding, reflecting earnings attributable to each share after accounting for all dilutive potential common shares. (The increase to $1.18 in Q3 2025 is positive, but the year-to-date decrease to $3.05 from $3.20 highlights the net income decline over nine months.)

Goodwill

An intangible asset that arises when one company acquires another for a price greater than the fair market value of its identifiable net assets. (A substantial balance of $4,475 million indicates significant past acquisitions, with a slight decrease from $4,477 million at October 31, 2024.)

Other comprehensive income (loss)

Unrealized gains or losses on certain investments, foreign currency translations, and pension adjustments that are not included in net income but affect total equity. (Shows fluctuations from items like foreign currency translation and derivative instruments, impacting total comprehensive income.)

Year-Over-Year Comparison

Compared to the prior year, Agilent Technologies demonstrated robust top-line growth in the third quarter of fiscal year 2025, with total net revenue up 10.1% to $1,738 million and net income surging 19.1% to $336 million. However, the nine-month year-to-date performance shows a more mixed picture, with revenue growing 5.8% to $5,087 million but net income declining 7.4% to $869 million. Key expense lines like cost of products (+17.5%) and SG&A (+10.8%) saw significant increases in Q3, contributing to the divergence between quarterly and year-to-date profitability. Capital allocation has also shifted, with share repurchases decreasing substantially year-over-year.

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value A New York Stock Exchange I

Filing Documents

• a-20250731.htm (10-Q) — 2068KB
• a-07312025xex311.htm (EX-31.1) — 12KB
• a-07312025xex312.htm (EX-31.2) — 11KB
• a-07312025xex321.htm (EX-32.1) — 6KB
• a-07312025xex322.htm (EX-32.2) — 5KB
• 0001090872-25-000036.txt ( ) — 11187KB
• a-20250731.xsd (EX-101.SCH) — 51KB
• a-20250731_cal.xml (EX-101.CAL) — 60KB
• a-20250731_def.xml (EX-101.DEF) — 491KB
• a-20250731_lab.xml (EX-101.LAB) — 802KB
• a-20250731_pre.xml (EX-101.PRE) — 650KB
• a-20250731_htm.xml (XML) — 2062KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 35 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 53 Item 4.

Controls and Procedures

Controls and Procedures 54 Part II. Other Information 55 Item 1.

Legal Proceedings

Legal Proceedings 55 Item 1A.

Risk Factors

Risk Factors 55 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 68 Item 5. Other Information 68 Item 6. Exhibits 69 Signature 70 2 Table of Contents

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) AGILENT TECHNOLOGIES, INC. CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (in millions, except per share data) (Unaudited) Three Months Ended Nine Months Ended July 31, July 31, 2025 2024 2025 2024 Net revenue: Products $ 1,230 $ 1,121 $ 3,616 $ 3,455 Services and other 508 457 1,471 1,354 Total net revenue 1,738 1,578 5,087 4,809 Costs and expenses: Cost of products 577 491 1,650 1,486 Cost of services and other 273 232 784 704 Total costs 850 723 2,434 2,190 Research and development 111 127 336 368 Selling, general and administrative 417 395 1,281 1,171 Total costs and expenses 1,378 1,245 4,051 3,729 Income from operations 360 333 1,036 1,080 Interest income 16 19 45 56 Interest expense ( 28 ) ( 22 ) ( 85 ) ( 64 ) Other income (expense), net 18 13 ( 3 ) 48 Income before taxes 366 343 993 1,120 Provision for income taxes 30 61 124 182 Net income $ 336 $ 282 $ 869 $ 938 Net income per share: Basic $ 1.18 $ 0.97 $ 3.05 $ 3.21 Diluted $ 1.18 $ 0.97 $ 3.05 $ 3.20 Weighted average shares used in computing net income per share: Basic 284 290 285 292 Diluted 285 291 285 293 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 Table of Contents AGILENT TECHNOLOGIES, INC. CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (LOSS) (in millions) (Unaudited) Three Months Ended Nine Months Ended July 31, July 31, 2025 2024 2025 2024 Net income $ 336 $ 282 $ 869 $ 938 Other comprehensive income (loss): Unrealized gain (loss) on derivative instruments, net of tax expense (benefit) of $ 1 , $ 0 , $ 0 and $( 1 ) 2 ( 3 ) ( 1 ) ( 3 ) Amounts reclassified into earnings related to derivative instruments, net of tax expense (benefit) of $ 2 , $( 1 ), $ 0 and $( 2 ) 5 ( 2 ) 2 ( 5 ) Foreign currency translation, net of tax expense (benefit) of $ 0 , $ 0 , $ 0 and $ 0 ( 5 ) 13 30 10 Net defined benefit pension cost